Sodium-glucose cotransporter-2 inhibitors: A new era of kidney care

Issue: BCMJ, vol. 64 , No. 9 , November 2022 , Pages 390-393 MDs To Be

There is a significant and growing burden of chronic kidney disease in Canada. Sodium-glucose cotransporter-2 inhibitors, a class of glucose-lowering medications originally developed for patients with type 2 diabetes, have been found to be of benefit in modifying both kidney and cardiovascular disease trajectories, irrespective of diabetic status or hemoglobin A1c control. They work by multiple mechanisms, including pleiotropic effects on the kidney and reducing weight, blood pressure, and uric acid, and consistently demonstrate kidney and cardiovascular protection in patients with chronic kidney disease. To address the morbidity and mortality of individuals living with kidney disease, we need to translate this robust clinical trial evidence into clinical practice, a task that will partly fall on primary care physicians, who manage a large proportion of patients with chronic kidney disease. While this process will not be without challenges, uptake of this class of medications will unequivocally change the outcomes for patients living with chronic kidney disease across the entire spectrum of kidney disease for years to come.

This review discusses clinical considerations and future use of sodium-glucose cotransporter-2 inhibitors in the context of kidney care.


Four million people currently live with chronic kidney disease in Canada, almost half of them under the age of 65.[1] Furthermore, the percentage of patients who progress to end-stage renal disease has grown by 35% since 2009.[1] Until recently, in addition to management of multimorbidities, the standard of care for patients with proteinuric kidney disease has been to initiate renin-angiotensin system inhibitor therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. This recommendation was based on considerable evidence from numerous clinical trials demonstrating a reduction in kidney disease progression, but not mortality, in patients who were on a renin-angiotensin system inhibitor, compared with those who were not.[2] However, since the first clinical trial demonstrating the renoprotective effects of renin-angiotensin system blockade in patients with diabetic kidney disease over 20 years ago, there has been a paucity of novel treatments to preserve renal function and modify the disease course of patients with chronic kidney disease,[3] until now. In a 2016 cardiovascular outcome trial of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), in patients with type 2 diabetes, empagliflozin use was unexpectedly found to be associated with a slower progression of kidney disease.[4] More specifically, in patients with type 2 diabetes, empagliflozin reduced the risk of progression of albuminuria, doubling of serum creatinine, kidney failure, and death.[4] Since then, there have been numerous cardiovascular outcome trials and a handful of recent landmark clinical trials that have convincingly and consistently demonstrated the protective effects of SGLT2i on the kidney.[4-9] Although the benefits of SGLT2i are not unique to the kidney, this review aims to discuss clinical considerations and future use of SGLT2i in the context of kidney care.

Mechanisms of action

SGLT2i, also known as the “gliflozins,” were originally developed for patients with type 2 diabetes.[10] They inhibit SGLT2, a low-affinity, high-capacity transport protein found in the proximal convoluted tubule of the nephron that is responsible for reabsorbing 90% of filtered glucose.[11-13] It was initially thought that by inhibiting reuptake of glucose and thus promoting glucosuria, SGLT2i could substantially lower blood glucose in hyperglycemic individuals independently of insulin and other glucose-lowering pathways.[11-13] While effective in those with preserved estimated glomerular filtration rate (eGFR), the glucose-lowering effects of SGLT2i are modest in patients with an eGFR of less than 45 mL/min/1.73 m2.[12,14] Nonetheless, the protective effects of SGLT2i on the kidney are independent of whether patients have glycemic control or established cardiovascular disease.[15,16]

A full discussion of the proposed physiological mechanisms by which SGLT2i confer renoprotection is beyond the scope of this article. In brief, emerging evidence implicates SGLT2i across a spectrum of distinct renal pathophysiological processes. For instance, in individuals with diabetic kidney disease, SGLT2i may attenuate nephron hyperfiltration, a known driver of intraglomerular hypertension and glomerular injury, by increasing sodium delivery to the macula densa, thereby restoring tubuloglomerular feedback.[17,18] SGLT2i also reduce cellular sodium and water reabsorption in the proximal tubule and promote paracellular sodium secretion through its actions on the sodium hydrogen exchanger, which is linked to SGLT2 by the membrane-associated protein MAP17.[19] Through reduction of sodium and glucose reabsorption in the proximal tubule, SGLT2i have been shown to shift tissue hypoxia in the cortical segment to the medullary segment of the nephron, which may increase production of erythropoietin, resulting in subsequent increases in red blood cell formation and oxygen-carrying capacity.[7,20] Finally, SGLT2i have been shown to attenuate vascular and renal reactive oxygen species, inflammation, and renal damage.[19]

In addition to these renal-specific benefits of SGLT2i, of which there are many others, the systemic effects of SGLT2i confer renoprotection as well. These include reductions in serum uric acid, body weight, and blood pressure, as well as benefits associated with reduced blood glucose levels and improved insulin sensitivity.[8]

Safety concerns in perspective

As with all medications, there are some safety concerns identified in the clinical trials reported to date. Importantly, these need to be weighed against the benefits of these medications, their true risks, and patient treatability. Although the absolute risk is low, patients on SGLT2i appear to be at increased risk of developing mycotic genital infections, which are typically not severe enough to warrant discontinuing SGLT2i therapy.[5,9,22] There have been suggestions that SGLT2i use may also increase the risk of urinary tract infections, lower limb amputations, and bone fractures, but recent meta-analyses have not supported this.[23,24] Patients with type 2 diabetes on SGLT2i may also be at increased risk of experiencing diabetic ketoacidosis with normal rather than elevated blood glucose levels, known as euglycemic diabetic ketoacidosis, so a higher index of suspicion is required in patients on SGLT2i.[25,26] In some earlier trials, there have also been rare reports of patients on SGLT2i developing necrotizing fasciitis of the perineum, also called Fournier gangrene.[9,27] However, it remains unclear whether gangrene development is associated with SGLT2i use.[28,29]

There have also been suggestions that SGLT2i therapy increases the risk of acute kidney injury in patients, but this has not been supported by evidence from large clinical trials.[4,5,27,30] In fact, a few meta-analyses have demonstrated a reduction in acute kidney injury risk for patients on SGLT2i.[23,24] A modest dip in GFR of approximately 5 mL/min/1.73 m2 predictably occurs when starting SGLT2i.[4-6] While this may appear concerning, the GFR dip appears to be protective in the long term for patients with and without diabetic kidney disease.[5,6,31-33] However, as with other medications, such as renin-angiotensin system inhibitors and antihyperglycemic agents, it may be prudent to stop SGLT2i when acutely ill or hospitalized to reduce the risk of volume depletion.

SGLT2i are not currently recommended for patients with type 1 diabetes, patients who are pregnant or breastfeeding, patients with bilateral renal artery stenosis, and patients with severe liver disease.[21] Currently, they should also not be started in patients with an eGFR of under 25 mL/min/1.73 m2, but a number of clinical trials that are examining starting these medications at a lower eGFR were being conducted at the time this article was written. Similarly, SGLT2i are not recommended for kidney transplant patients; however, there are a handful of published case series that have reported good effect of these medications on this patient population, and clinical trials are being planned to investigate this further.

Recommended guidelines for clinical use

The Kidney Disease: Improving Global Outcomes (KDIGO) working group and Diabetes Canada recommend that patients with type 2 diabetes, chronic kidney disease, and an eGFR greater than 30 mL/min/1.73 m2 be treated with an SGLT2i in conjunction with metformin.[34,35] The choice of SGLT2i should consider patient factors such as patient comorbidities and side effect profiles as well as which SGLT2i have documented renal and cardiovascular benefits.[33,34] The KDIGO working group also recommends that once SGLT2i are initiated, they can be safely continued in patients whose eGFR drops below 30 mL/min/1.73 m2, but as mentioned above, these medications should be withheld during bouts of prolonged fasting, surgeries, or critical medical illness.[34,35] At the time of writing, there are no other local or national guidelines regarding the use of SGLT2i for chronic kidney disease in nondiabetic patients. However, there is reasonable evidence to suggest that at least dapagliflozin is beneficial for chronic kidney disease patients irrespective of diabetic status.[6]

Clinical caveats

According to British Columbia guidelines, referral to nephrology by primary care is typically recommended when patients reach an eGFR of 30 mL/min/1.73 m2.[36] This implies that, with respect to SGLT2i, primary care professionals will likely be tasked with identifying candidates most likely to benefit from SGLT2 inhibition, initiating SGLT2i therapy, and monitoring patients who are on them. Currently, as others have pointed out, considerable challenges remain in the translation of SGLT2i trial results into clinical practice.[12,21] First, there is likely to be resistance to SGLT2i uptake by medical professionals who are not comfortable managing patients on SGLT2i or who are not familiar with the clinical trial evidence. Therefore, patients who are candidates for SGLT2i therapy may go unrecognized. Second, identification of SGLT2i candidates requires detection of early signs of kidney disease through rigorous screening programs. There may, however, be less ability to implement such programs in rural and remote regions of BC where access to laboratory services and health care providers may be limited. Last, coverage of the cost of medication is a significant barrier for chronic kidney disease patients. In BC, both empagliflozin and dapagliflozin are covered by PharmaCare for patients with type 2 diabetes, but they are available only for patients who have failed two oral therapies.[37] Thus, for patients not meeting these criteria who face financial difficulties, prescribing SGLT2i such as dapagliflozin for chronic kidney disease may not be a suitable option. In the next 10 years, evidence will continue to emerge regarding the efficacy of SGLT2i for patients with chronic kidney disease and how to properly integrate SGLT2i into clinical practice.


SGLT2i, a class of antihyperglycemic agents originally developed for type 2 diabetes, have now been demonstrated to slow chronic kidney disease progression independent of underlying diabetes or cardiovascular disease. The ability to slow progression of chronic kidney disease is of immense value given the large burden of illness that accrues with chronic kidney disease. This class of medications should be withheld during bouts of acute illness, as one holds angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other medications to avoid untoward side effects. While there is still much that remains to be discovered about this class of medications, they should arguably be a cornerstone of chronic kidney disease treatment in the current era. We must be conscientious and diligent to ensure that uptake of SGLT2i is robust by increasing education and awareness about these medications, while ensuring that they are accessible to all. Given the socioeconomic disparities in those who develop chronic kidney disease and its impact on earning potential, there is a need to enable equitable access to these medications. Without attention to these important facts, we risk amplifying existing disparities.[38] SGLT2i are an exciting, safe, and effective therapeutic option for individuals with chronic kidney disease and are well poised to transform kidney care for years to come.

Competing interests

None declared.


The author would like to thank Dr Adeera Levin for her guidance and valuable suggestions during the development of this article.

This article has been peer reviewed.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.


1.    The Kidney Foundation of Canada. Facing the facts. 2020. Accessed 20 February 2022.

2.    Akbari A, Clase CM, Acott P, et al. Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney Dis 2015;65:177-205.

3.    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.

4.    Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334.

5.    Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-2306.

6.    Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-1446.

7.    Hesp AC, Schaub JA, Prasad PV, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: A promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int 2020;98:579-589.

8.    Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018;61:2098-2107.

9.    Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.

10.    Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia 2018;61:2079-2086.

11.    Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev 2021;26:623-642.

12.    Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis 2021;77:94-109.

13.    Scheen AJ. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:556-577.

14.    Cherney DZ, Cooper ME, Tikkanen I, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018;93:231-244.

15.    Heerspink HJL, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017;28:368-375.

16.    Cannon CP, Perkovic V, Agarwal R, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c < 7%: Results from the CREDENCE trial. Circulation 2020;141:407-410.

17.    Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018;94:26-39.

18.    Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 2020;16:317-336.

19.    Wilcox C. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension 2020;75:894-901.

20.    Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: Modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis 2021;77:280-286.

21.    Dubrofsky L, Srivastava A, Cherney DZ. Sodium-glucose cotransporter-2 inhibitors in nephrology practice: A narrative review. Can J Kidney Health Dis 2020;7:2054358120935701.

22.    Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab 2019;21:34-42.

23.    Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845-854.

24.    Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: A systematic review and meta-analysis. BMJ Open 2019;9:e022577.

25.    Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J Diabetes Investig 2016;7:135-138.

26.    Zhang L, Tamilia M. Euglycemic diabetic ketoacid­osis associated with the use of a sodium-glucose cotransporter-2 inhibitor. CMAJ 2018;190:E766-E768.

27.    Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357.

28.    Wang T, Patel SM, Hickman A, et al. SGLT2 inhibitors and the risk of hospitalization for Fournier’s gangrene: A nested case-control study. Diabetes Ther 2020;11:711-723.

29.    Silverii GA, Dicembrini I, Monami M, Mannucci E. Fournier’s gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22:272-275.

30.    Perlman A, Heyman SN, Matok I, et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 2017;27:1108-1113.

31.    Sridhar VS, Tuttle KR, Cherney DZI. We can finally stop worrying about SGLT2 inhibitors and acute kidney injury. Am J Kidney Dis 2020;76:454-456.

32.    Oshima M, Jardine MJ, Agarwal R, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int 2021;99:999-1009.

33.    Kraus BJ, Weir MR, Bakris GL, et al. Characterization and implications of the initial estimated glomerular filtration rate “dip” upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 2021;99:750-762.

34.    Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98:S1-S115.

35.    Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes 2018;42(Suppl 1):S88-S103.

36.    Government of British Columbia. Chronic kidney disease – identification, evaluation and management of adult patients. BC Guidelines. 2019. Accessed 20 February 2022.

37.    BC Renal Agency. CKD e-learning – SGLT-2 inhibitors and CKD. 2021. Accessed 19 May 2021.

38.    Crews DC, Liu Y, Boulware LE. Disparities in the burden, outcomes, and care of chronic kidney disease. Curr Opin Nephrol Hypertens 2014;23:298-305.

Mr Cau is a fourth-year student in the Faculty of Medicine at the University of British Columbia.

Alessandro Cau, BSc (Hons). Sodium-glucose cotransporter-2 inhibitors: A new era of kidney care. BCMJ, Vol. 64, No. 9, November, 2022, Page(s) 390-393 - MDs To Be.

Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.

For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit

BCMJ Guidelines for Authors

Leave a Reply